<DOC>
	<DOCNO>NCT01405846</DOCNO>
	<brief_summary>We go use special type bronchoscopy test examine patient previous surgical treatment lung cancer head neck cancer . The aim determine ) whether identify precancerous change airways b ) whether type test acceptable c ) get initial idea whether new drug call gefitinib effect precancerous area airway .</brief_summary>
	<brief_title>Feasibility Study Estimate Number Patients With Precancerous Areas Their Airways Response Gefitinib</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Age 18 year Resected NSCLC Squamous cell Head &amp; Neck cancer treat curatively All treatment , include adjuvant treatment radiotherapy and/or chemotherapy complete least 3 month prior study entry ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 Suitable flexible bronchoscopy Able give sign informed consent Adequate haematological , kidney liver function : Serum alanine transaminase ( ALT ) ≤2.5 x upper limit normal ( ULN ) Total serum bilirubin ≤1.5 x ULN Absolute neutrophil count ( ANC ) ≥1500/μL Platelets ≥100,000/μL Haemoglobin ≥9.0 g/dL Sufficient renal function allow administration contrast medium ( line Royal College Radiologists guideline ) . In addition , follow inclusion criterion must meet screen period order confirm eligibility study treatment No evidence malignant disease activity screen High grade dysplasia autofluorescence bronchoscopy analysis No evidence pulmonary fibrosis interstitial lung disease screen CT Diagnosis second malignancy within 5 year date enrolment , except basal cell carcinoma , squamous cell skin cancer , situ carcinoma cervix uteri adequately treat evidence recurrent disease 12 month Evidence severe uncontrolled systemic disease psychiatric disorder would interfere patient 's safety Known severe hypersensitivity Gefitinib excipients product Past medical history interstitial lung disease , druginduced interstitial disease , radiation pneumonitis require steroid treatment evidence clinically active interstitial lung disease Preexisting idiopathic pulmonary fibrosis History allergy contrast medium Insufficient lung function determine either clinical examination arterial oxygen tension ( PaO2 ) &lt; 9.3kpa Inability swallow oral medication Presence active inflammatory bowel disease , partial complete bowel obstruction chronic diarrhoea condition would interfere absorption oral drug . Past medical history keratitis Past medical history Sjogren 's syndrome Pregnant breastfeed Male female patient ( childbearing age ) use , willing use , protocol mandate contraception Prior EGFR inhibitor use . Concurrent medication know potent CYP3A4 inhibitor inducer and/or dose within 7 day date enrolment ( e.g.. ketoconazole , rifampin , phenytoin , carbamazepine , barbiturates herbal preparation contain St John 's wort/Hypericum perforatum etc . ) use concomitant medication incompatible study drug ( see SmPC ) Current treatment another therapeutic clinical trial previous investigational agent last 12 week ( supportive care trial nontreatment trial allow ) Previous enrolment treatment present study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>